Effector Therapeutics News Today

This modeling study uses Cancer Intervention and Surveillance Modeling Network models and national data on breast cancer incidence, mammography

EFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 10,700 shares, a growth of 148.8% from the March 31st total of 4,300 shares. Based on an average daily trading volume, of 30,800 […]

EFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Free Report) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 10,700 shares, an increase of 148.8% from the March 31st total of 4,300 shares. Based on an average trading volume of 30,800 shares, […]

Top-line data from the phase II Kickstart study of Effector Therapeutics Inc.’s tomivosertib as a frontline treatment of non-small-cell lung cancer failed to produce data strong enough to continue development in the indication. The company has decided to halt the study, move ahead with a separate, investigator-sponsored study of tomivosertib in acute myeloid leukemia and focus on another drug in its pipeline for treating breast cancer.

EFFECTOR Therapeutics, Inc. (EFTR) announced Thursday topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 =50%.

Shares of eFFECTOR Therapeutics, Inc. (EFTR) slipped over 80% on Thursday morning after the company said it would end the development of its tomivosertib non-small cell lung cancer treatment after phase 2 data showed no positive results.

Shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTRW – Get Free Report) shot up 6.7% during mid-day trading on Tuesday . The company traded as high as $0.16 and last traded at $0.16. 19,060 shares changed hands during mid-day trading, a decline of 14% from the average session volume of 22,064 shares. The stock had previously closed […]

By Chris Wack eFFECTOR Therapeutics shares were down 8% at $9.18 after the company entered into a definitive agreement with a single healthcare-focused...

-  Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- -  Review of recently announced interim...

EFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Free Report) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 434,000 shares, an increase of 72.8% from the October 31st total of 251,100 shares. Based on an average trading volume of 749,100 shares, the short-interest ratio […]